Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.45
Ask: 1.546
Change: 0.00 (0.00%)
Spread: 0.096 (6.621%)
Open: 1.50
High: 0.00
Low: 0.00
Prev. Close: 1.50
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re possible acquisition

30 Dec 2015 07:00

RNS Number : 3726K
Silver Falcon PLC
30 December 2015
 

30 December 2015

SILVER FALCON PLC

("Silver Falcon" or the "Company")

 

Proposed acquisition of Lime Holdings Limited ("Lime")

 

Silver Falcon plc (LSE:SILF), the listed special purpose acquisition company, refers to its announcement of 23 December 2015 and is pleased to advise that it has entered into a non-binding Memorandum of Understanding with the board and principal shareholder in Lime Holdings Limited ("Lime") regarding a possible acquisition of 100% of the share capital of Lime by way of a share for share exchange ("Transaction").

Lime is an Australian unlisted public company which operates in the financial technology sector. It has developed an innovative platform for the insurance industry which facilitates the automated delivery of insurance to end users.

Lime has recently relocated its headquarters to the UK and is developing commercial partnerships in the UK and on an international basis.

Whilst a general understanding on the terms of the Transaction has been reached, these terms are subject to due diligence, a fundraising, and re-listing of the enlarged group on the London Stock Exchange. Accordingly there is no certainty that it will be completed.

If the Transaction is completed, it will constitute a reverse takeover under the Listing Rules. As the Company is unable to provide full disclosure under Rule 5.6.15 of the Listing Rules, the Company has requested a continuation of the current suspension of trading in its shares.

Further announcements will be made in due course as the Transaction progresses.

 

For further information please contact:

Silver Falcon: Tim Le Druillenec (Company Secretary), 07874 762821

Media enquiries: Jennifer Renwick, jennifer.renwick@camarco.co.uk, 0203 757 4994

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQTLBPTMBTTBAA
Date   Source Headline
18th Nov 202211:05 amRNSSecond Price Monitoring Extn
18th Nov 202211:00 amRNSPrice Monitoring Extension
27th Oct 20224:40 pmRNSSecond Price Monitoring Extn
27th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Oct 20222:05 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
29th Sep 20228:00 amRNSHalf-year Report
1st Sep 20228:45 amRNSPresentation at H.C. Wainwright Global Conference
22nd Aug 20227:00 amRNSAppointment of Director of Quality
15th Aug 20227:00 amRNSApproval and Issuance of Antibody Patent
10th Aug 20227:00 amRNSAppointment of Medical Director
9th Aug 20222:06 pmRNSSecond Price Monitoring Extn
9th Aug 20222:00 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSNew Custom R&D Facility Opening
8th Jul 202212:25 pmRNSInvestor Webinar Recording
1st Jul 202212:19 pmRNSChange of Registered Office
30th Jun 20223:29 pmRNSResult of Annual General Meeting
27th Jun 20227:00 amRNSInvestor Webinar
7th Jun 20222:17 pmRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSDirector/PDMR Shareholding
27th May 20222:05 pmRNSSecond Price Monitoring Extn
27th May 20222:00 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSImmuno-Oncology Summit Europe Presentation
29th Apr 20225:39 pmRNSFinal Results for the Year Ended 31 December 2021
21st Mar 20224:42 pmRNSSecond Price Monitoring Extn
21st Mar 20224:36 pmRNSPrice Monitoring Extension
21st Mar 20222:06 pmRNSSecond Price Monitoring Extn
21st Mar 20222:01 pmRNSPrice Monitoring Extension
16th Mar 20227:00 amRNSCBR Update
4th Mar 20222:05 pmRNSSecond Price Monitoring Extn
4th Mar 20222:00 pmRNSPrice Monitoring Extension
4th Mar 202211:05 amRNSSecond Price Monitoring Extn
4th Mar 202211:00 amRNSPrice Monitoring Extension
16th Feb 20227:00 amRNSHEMO-CAR-T pre-IND Meeting Request
12th Jan 20227:00 amRNSHemogenyx Pharmaceuticals Partnership with Selexis
5th Jan 20227:00 amRNSH.C. Wainwright Bioconnect Conference
22nd Dec 20212:05 pmRNSSecond Price Monitoring Extn
22nd Dec 20212:00 pmRNSPrice Monitoring Extension
22nd Dec 202111:06 amRNSSecond Price Monitoring Extn
22nd Dec 202111:01 amRNSPrice Monitoring Extension
20th Dec 20217:00 amRNSHemo-CAR-T partnership with WuXi ATU
13th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20218:55 amRNSHEMO-CAR-T pre-IND Meeting Request
24th Nov 20212:38 pmRNSConvertible Loans Repayment
18th Oct 20217:00 amRNSLease of New York Mink Building Custom Laboratory
13th Oct 20218:30 amRNSCDX Licence Agreement
12th Oct 20214:41 pmRNSSecond Price Monitoring Extn
12th Oct 20214:36 pmRNSPrice Monitoring Extension
30th Sep 20218:00 amRNSHalf-year Report
2nd Sep 20217:00 amRNSU.S. Approval of Monoclonal Antibody Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.